Could GLP-1 Users Could Risk Potential Risk of Vision Loss

Written by on September 22, 2026

Dozens of Americans have filed personal injury lawsuits against the makers of popular GLP-1 drugs, like Ozempic, Wegovy and Mounjaro, claiming they were not properly warned of the risk of a rare type of sudden vision loss, called nonarteritic anterior ischemic optic neuropathy, or NAION, when taking the medications.  Researchers have been studying a possible link between GLP-1 drugs and this eye condition in recent years after a possible safety signal was reported from a single health center in Boston in 2024, but so far, no study has proven these drugs are the cause. 

Advertisements

Novo Nordisk, the maker of Ozempic and Wegovy, said they take “all reports of adverse events very seriously,” and pushed back against these claims, stating, “Novo believes the personal injury lawsuits filed in the U.S. are without merit and are vigorously defending them,” a spokesperson told ABC News. Adding, “Novo is committed to patient safety and continuously monitors the safety profile of our GLP-1 RA products. Should emerging safety data warrant further action, appropriate measures will be implemented in accordance with regulatory requirements.”

A spokesperson for Lilly, who manufactures Zepbound and Mounjaro, told ABC News, “Patient safety is Lilly’s top priority. We actively monitor, evaluate, and report safety information for all our medicines to the FDA. As part of our routine safety review process, we have ongoing discussions with regulators regarding potential safety topics, and we will continue to review data, including any data regarding ophthalmic issues.”

Source: ABC News


Current track

Title

Artist